
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

AI predicts an enzyme’s substrate
Researchers from Germany, Sweden and India have reported an AI method that predicts whether an enzyme can work with a specific substrate. In...

The innovative power of the chemical industry assembled
From cosmetics to medical treatments, from agriculture to the fabrics that make out our clothes – chemistry is ubiquitously needed in countless...

Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

Syngenta partners with Biotalys
Basel-headquartered Syngenta Crop Protection and Biotalys NV (Ghent) will collaborate to research, develop and commercialise protein-based biocontrol...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

LSP Dementia Fund closes at €260m
Investors included the Alzheimer’s Association, the European Investment Fund EIF, several unnamed global pharmaceutical, and insurance companies,...